Is Moderna (MRNA) a Buy Right Now?
A plain-English read on Moderna stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Moderna is currently priced at $54.07. The stock is holding above its 200-day average of $44.14, which is a common gauge used to identify the long-term trend. When the price stays above this level, it suggests that the broader direction remains upward.
The RSI—a gauge of whether a stock has climbed too far, too fast—is at 36.7. This indicates the stock is not currently overbought. With the price near the recent support floor of $53.85, the data points toward a buy signal for those looking at these specific levels.
Should you buy Moderna stock?
The data supports a buy position as the price holds near its support floor of $53.85. This is an objective look at the numbers, not a guarantee of future performance. Always weigh your own risk tolerance before entering any position.
Is MRNA a good stock for beginners?
Moderna is a large company, but its negative P/E ratio—a measure of a company's price relative to its earnings—shows it is not currently profitable. This creates higher volatility, or price swings, which can be challenging for those just starting their investment journey.
What's driving MRNA right now
The price remains above the 200-day average of $44.14.
The stock is currently trading near the recent support level of $53.85.
The P/E ratio is -13.6, reflecting that the company is currently not generating a profit.
The stock experienced a day change of -5.17%.
What Moderna actually does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna by the numbers
Wall Street consensus on MRNA is Hold. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Moderna's earnings history
Earnings per share for Moderna's last 4 reported financial years, as filed — EPS has fallen over that span. We don't hold analyst consensus estimates for these periods, so no beat-or-miss judgement is shown.
| Period end | EPS reported |
|---|---|
| 2025-12-31 | -7.26 |
| 2024-12-31 | -9.27 |
| 2023-12-31 | -12.34 |
| 2022-12-31 | 21.26 |
Who owns Moderna?
Institutions — pension funds, asset managers, index providers — hold 78.8% of MRNA, and the concentration matters: the largest single holder alone controls 11.51% of the company.
| Holder | Shares | % held |
|---|---|---|
| 45.67M | 11.51% | |
| 29.64M | 7.47% | |
| 22.87M | 5.76% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Moderna insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Moderna, 2 were sales and 0 were open-market purchases; the other 4 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | AWARD / VEST | 53.3K | $1.0M | |
| 2026-07-15 | SELL | 53.3K | $3.6M | |
| 2026-07-02 | AWARD / VEST | 1.5K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading MRNA?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. 4 disclosures name MRNA — filed by 2 separate members and worth $18K–$95K combined (filings report bands, never exact amounts). 0 purchase-side, 4 sale-side, most recently on 2021-07-22.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2021-07-22 | SELL | $1,001 - $15,000 | |
| 2021-01-29 | SELL | $15,001 - $50,000 | |
| 2021-01-29 | SELL | $1,001 - $15,000 |
Names withheld — plus 1 more record not shown.
See which membersWith the price currently above its 200-day average and near support, the data indicates a buy for those who understand the risks.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice MRNA risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about MRNA
Should I buy MRNA stock?+
The data shows a buy signal because the price is holding above the 200-day average of $44.14.
Is MRNA a good long-term investment?+
The stock is currently trading above its 200-day average, though the negative P/E ratio of -13.6 highlights the risks involved.
Is MRNA a buy or a sell?+
Based on the current data, the indicators suggest a buy as the price sits near the $53.85 support level.
Is MRNA overvalued?+
With an RSI of 36.7, the stock is not currently in overbought territory, though it has traded as low as $22.28 in the last year.
Is MRNA a good stock for beginners?+
Beginners should be cautious because the negative P/E ratio of -13.6 suggests the company is not yet profitable.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Moderna (MRNA) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-07-24 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.